Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Alcohol and drug interactions].

C M Oneta1

  • 1Département de Médecine interne, CHUV/PMU, Lausanne. Carl.Oneta@chuv.hospvd.ch

Therapeutische Umschau. Revue Therapeutique
|May 11, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Pancreatic carcinoma?].

Praxis·2007
Same author

[Alcoholic and non-alcoholic steatohepatitis].

Therapeutische Umschau. Revue therapeutique·2004
Same author

Risk factors in alcohol associated breast cancer: alcohol dehydrogenase polymorphism and estrogens.

International journal of oncology·2004
Same author

Age and bioavailability of alcohol.

Zeitschrift fur Gastroenterologie·2001
Same author

Cholestatic hepatitis A complicated by acute renal insufficiency.

Zeitschrift fur Gastroenterologie·2001
Same author

Cushing's syndrome in an 81-year-old patient treated with budesonide and amiodarone.

European journal of gastroenterology & hepatology·2000
Same journal

[Multimodal Cardiac Imaging: New Developments for Clinical Practice].

Therapeutische Umschau. Revue therapeutique·2026
Same journal

[Coronary angiography: From cardiac catheterization to advanced interventional cardiovascular imaging].

Therapeutische Umschau. Revue therapeutique·2026
Same journal

[Athlete's heart: role of cardiac imaging in the prevention of sudden cardiac death].

Therapeutische Umschau. Revue therapeutique·2026
Same journal

[Multimodal imaging in cardiac amyloidosis and cardiac sarcoidosis].

Therapeutische Umschau. Revue therapeutique·2026
Same journal

[Inflammatory Heart Disease: The Role of Multimodality Cardiac Imaging in Myocarditis and Pericarditis].

Therapeutische Umschau. Revue therapeutique·2026
Same journal

State-of-the-Art Cardiac Imaging

Therapeutische Umschau. Revue therapeutique·2026
See all related articles

Chronic alcohol use boosts the microsomal ethanol-oxidizing system (MEOS), increasing alcohol-drug interactions. Awareness among doctors and patients is crucial to prevent severe adverse effects.

Area of Science:

  • Pharmacology and Toxicology
  • Hepatology
  • Drug Metabolism

Context:

  • Alcohol metabolism primarily occurs in the liver via alcohol dehydrogenase (ADH).
  • Chronic alcohol consumption significantly induces the microsomal ethanol-oxidizing system (MEOS), particularly cytochrome P450 2E1.
  • Gastric alcohol dehydrogenase (ADH) contributes to first-pass metabolism, though its role is minor compared to hepatic pathways.

Purpose:

  • To review the roles of different alcohol metabolism pathways, focusing on the increased significance of MEOS after chronic alcohol intake.
  • To highlight the common site of alcohol-drug interactions mediated by the ethanol-inducible cytochrome P450 2E1.
  • To discuss clinically relevant alcohol-drug interactions and emphasize the need for increased awareness.

Summary:

Related Experiment Videos

  • Alcohol metabolism shifts from ADH to MEOS with chronic alcohol use, with MEOS activity increasing four- to ten-fold.
  • The MEOS pathway, involving cytochrome P450 2E1, metabolizes ethanol and activates numerous drugs, leading to frequent alcohol-drug interactions.
  • First-pass metabolism in the stomach via gastric ADH is a minor contributor to overall ethanol metabolism.

Impact:

  • Increased understanding of how chronic alcohol consumption alters drug metabolism pathways.
  • Identification of the MEOS system as a critical site for clinically significant alcohol-drug interactions.
  • Emphasizes the necessity of educating healthcare providers and patients to mitigate risks associated with alcohol-drug interactions.